Compounds > tipifarnib
Page last updated: 2024-09-04

tipifarnib and imatinib mesylate

tipifarnib has been researched along with imatinib mesylate in 11 studies

Compound Research Comparison

Studies
(tipifarnib)		Trials
(tipifarnib)		Recent Studies (post-2010)
(tipifarnib)		Studies
(imatinib mesylate)		Trials
(imatinib mesylate)		Recent Studies (post-2010) (imatinib mesylate)
309929411,4779605,773

Protein Interaction Comparison

ProteinTaxonomytipifarnib (IC50)imatinib mesylate (IC50)
Tyrosine-protein kinase ABL1Homo sapiens (human)0.31
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.1

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's11 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Sánchez De Cos Escuín, J1
Smit, EF1
Karp, JE; Lancet, JE1
Tauchi, T1
Kano, Y; Komatsu, N; Miyoshi, T; Muroi, K; Nagai, T; Nakamura, M; Ohmine, K; Ozawa, K1
Odenike, O; Tefferi, A1
Grever, MR1
Borner, MM1
Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN1
Hayashi, Y1
Cortes, J; Ebarb, T; Faderl, S; Garcia-Manero, G; Giles, F; Jones, D; Kantarjian, H; O'Brien, S; Quintás-Cardama, A; Thomas, D1

Reviews

7 review(s) available for tipifarnib and imatinib mesylate

ArticleYear
[New therapeutic targets and strategies in lung cancer].
    Archivos de bronconeumologia, 2002, Volume: 38, Issue:8

    Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2002
Farnesyl transferase inhibitors in myeloid malignancies.
    Blood reviews, 2003, Volume: 17, Issue:3

    Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Enzyme Inhibitors; Farnesyltranstransferase; Hematologic Neoplasms; Humans; Imatinib Mesylate; Imidazoles; Leukemia, Myeloid, Acute; Models, Biological; Myeloproliferative Disorders; Piperazines; Pyrimidines; Quinolones; ras Proteins; Signal Transduction

2003
[Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2004, Volume: 45, Issue:1

    Topics: Animals; Benzamides; Chromosome Aberrations; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Piperidines; Pyridines; Pyrimidines; Quinolones; Randomized Controlled Trials as Topic; Thionucleotides

2004
Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
    Seminars in oncology, 2005, Volume: 32, Issue:4

    Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins

2005
New drugs in acute myeloid leukemia.
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:8

    Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Evaluation; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Imatinib Mesylate; Leukemia, Myeloid; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Thionucleotides

2003
[Molecular targets in colon cancer].
    Therapeutische Umschau. Revue therapeutique, 2006, Volume: 63, Issue:4

    Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib

2006
[Problems in the current target therapy of malignancies].
    Voprosy onkologii, 2005, Volume: 51, Issue:5

    Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab

2005

Trials

1 trial(s) available for tipifarnib and imatinib mesylate

ArticleYear
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
    Cancer, 2007, Nov-01, Volume: 110, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Maximum Tolerated Dose; Middle Aged; Piperazines; Pyrimidines; Quinolones

2007

Other Studies

3 other study(ies) available for tipifarnib and imatinib mesylate

ArticleYear
[New data presented at ASCO 2002 concerning small cell bronchial cancer].
    Revue de pneumologie clinique, 2002, Volume: 58, Issue:5 Pt 2

    Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Carcinoma, Small Cell; Cisplatin; Deoxycytidine; Etoposide; Gemcitabine; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Prognosis; Pyrimidines; Quinolones; Smoking; Smoking Prevention; Survival Analysis; Treatment Outcome

2002
Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines.
    Biochemical pharmacology, 2005, Jun-01, Volume: 69, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Blast Crisis; Cell Cycle; Cell Line, Tumor; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Fusion Proteins, bcr-abl; Growth Inhibitors; Humans; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Quinolones

2005
[Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:2

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Biomarkers, Tumor; Child; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Promyelocytic, Acute; Loss of Heterozygosity; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Quinolones; Rituximab; Tretinoin

2007